• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

MHE Question of the Week

News
Article
Pages: 1

Should site-neutral payment rules and policies be extended to commercial payers, payment for physician-administered drugs, and services delivered in on-campus hospital outpatient departments?

We want to know what you’re thinking! Every Tuesday morning, the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. We'll tally your answers and publish the results on Friday by 4 p.m. ET.

Some background on this week’s question

Payment for outpatient services has traditionally varied depending on where the services were delivered. Typically, they have been higher at hospital outpatient facilities than at physician offices. But as hospitals have bought physician practices and expanded their outpatient facilities, payers and others have pushed for “site-neutral” payment that pays the same amount for the service, regardless of where it is delivered. Medicare already has some site-neutral payment policies.

Now Congress and regulators are considering legislation and rules that would extend site-neutral payment further to include physician-administered drugs and outpatient facilities located on hospital campuses. Some proposals would also apply site-neutral payment rules to commercial payers.

Hospitals and some other groups are fighting site-neutral payment, arguing that patients seen in hospital facilities receive more coordinated care and are often more medically complex.

Should site-neutral payment rules and policies be extended to commercial payers, payment for physician-administered drugs, and services delivered in on-campus hospital outpatient departments?

Yes
No

Related Videos
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Related Content
© 2024 MJH Life Sciences

All rights reserved.